Trombovazim - enzyme preparation belonging to the group of fibrinolytic agents to facilitate the destruction of fibrin, the resorption of fresh, not yet formed clots. The drug is used for complex treatment  Trombovazim per pack
   venous insufficiency. Also conducted research on the effectiveness of the drug in the treatment of myocardial infarction, acute coronary syndrome, but for this indication the drug is not registered, and does not apply. The drug Trombovazim available in tablets and capsules with different contents of active substance (trombovazima). The drug has anti-thrombolytic, fibrinolytic, cardioprotective action. Trombovazim is low toxic drug. Trombovazim not affect blood clotting, the duration of bleeding does not reduce the level of platelets in the blood.

Trombovazim: instructions for use

Trombovazim used to normalize the venous circulation, improve the protection of the walls of veins, prevents the formation of new blood clots in the venous insufficiency. The drug has a triple mechanism of action:

  • The dissolution of existing clots in the veins of the lower extremities;
  • The normalization of microcirculation, recovery, and increase the speed of venous lymphatic current, reducing the edema of the lower limbs, reduction of pain;
  • Anti-inflammatory action, strengthen and restore the integrity of vein walls, prevents the formation of new blood clots by stopping fibrin polymerization (neglobulyarnogo, high-protein fibers which are the main structural component of blood clots).

The drug Trombovazim also promotes rapid healing of venous ulcers.

When receiving Trombovazima guide to the drug dosage and adjusts the frequency of administration. Doctors generally prescribed standard dosage of the drug, based on the clinical picture. Thus, the maximum daily dose Trombovazima instruction defines as 2000ED. Trombovazimom overdoses were reported.

The recommended treatment regimen involves two doses of the drug Trombovazim day 1-2 capsules / tablets for 20 days. The drug is recommended to take 30-40 minutes before meals.

In the absence of the expected effect of the Trombovazima seek medical advice. At the beginning of treatment may increase Trombovazimom varicose disease, chronic venous insufficiency.

The main side effects of the drug Trombovazim include:

  • Allergic reactions;
  • Malfunctions of the gastrointestinal (diarrhea, nausea, vomiting, a feeling of heaviness in the stomach).

The drug Trombovazim does not affect the person's ability to drive vehicles, as well as to perform work requiring special attention and speed of physical and mental reactions, because its components are not substances regulating psychomotor human condition.

The drug Trombovazim safe due to its low toxicity. When receiving Trombovazima necessary to consider its interactions with other drugs groups. Drugs such as heparin, aspirin, dipyridamole promote strengthening Trombovazima antithrombotic effect, while the risk of increased bleeding.

Antibiotics  Trombovazim tablets
 tetracyclines (chlortetracycline hydrochloride, tetracycline, oxytetracycline hydrochloride) enhance the effect of fibrinolytic agents. If necessary, the simultaneous use of drugs of the tetracycline group and Trombovazima advised to observe an interval of reception from 30 to 40 minutes.

Trombovazim: Contraindications

Contraindications Trombovazim can be relative or absolute.

Absolute contraindications to the use of Trombovazima are:

  • hypersensitivity to the drug Trombovazim, allergic reactions to the use of drugs in history;
  • duodenal ulcer and stomach in the acute phase;
  • Pregnancy, breast-feeding;

Relative contraindications to the use of Trombovazima are:

  • Patient age of 18 years (the study of efficacy and safety of the drug has not been in this age group);
  • Receiving Trombovazima preparations containing the divalent metal salts (magnesium, iron, zinc, potassium), and tetracycline antibiotics. If necessary, the simultaneous use of these groups of drugs should consult with a physician. When treating Trombovazimom instructions to take medication separate from other medication at intervals up to 40 minutes;
  • The threat of bleeding in the esophagus, duodenal ulcer and stomach in remission, chronic obstructive pulmonary disease.

Trombovazim: analogues of the drug

The basis of the treatment of chronic venous insufficiency used drugs and groups venotoniki fleboprotektorov. Trombovazim differs from analogues provide integrated actions, destroying existing blood clots and reducing the risk of thrombus formation of new blood vessels in the lower extremities. Trombovazim analogs which have a number of contraindications, is a safe drug, which is effective in the elimination of symptoms does not increase the risk of bleeding.

Also Trombovazim analogs which show the effectiveness of a recovery in the elasticity of the vessel wall, has no serious side effects and is approved for use in a broad group of patients.

According to the developers of the drug, Trombovazim is a unique tool, which is used in the development of nuclear physics and to achieve a method of electron-beam immobilization, allowing modification of biologically active substances by means of radiation-activated polymer. Trombovazim is a unique composition of drug analogues do not exist. Active substance represented Trombovazima proteinase enzyme supplemented active polymer which protects the enzyme from attack and destruction by the immune system.

Trombovazim: reviews of patients medical opinion

Trombovazim is safe to use the drug, aimed at a radical change in the clinical picture. Trombovazim, reviews of which indicate a decrease in disease symptoms, swelling of the lower extremities, fatigue and heaviness in the legs, is positioned as an effective tool for the treatment of blood clots and prevent the subsequent thrombosis. However, Trombovazim, reviews of which can be found on the Internet, according to the doctors is not as effective in removing blood clots. The traditional practice is used to remove blood clots or intravenous administration of drugs directly into the clot itself. Present thrombolytic efficacy in tablets is extremely difficult.